Aspen Aerogels (NYSE:ASPN) Updates Q3 2026 Earnings Guidance

Aspen Aerogels (NYSE:ASPN) updated its third quarter 2026 earnings guidance on Thursday. The company provided EPS guidance of -0.110–0.070 for the period, compared to the consensus EPS estimate of -0.130. The company issued revenue guidance of $65.0 million-$80.0 million, compared to the consensus revenue estimate of $56.6 million.

Analyst Upgrades and Downgrades

ASPN has been the subject of several research reports. Barclays increased their target price on Aspen Aerogels from $3.00 to $4.00 and gave the company an “underweight” rating in a research report on Monday, May 11th. Wall Street Zen upgraded Aspen Aerogels from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aspen Aerogels in a research note on Wednesday, June 24th. Finally, Roth Capital reiterated a “buy” rating and issued a $5.75 price objective on shares of Aspen Aerogels in a report on Friday, May 8th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $5.19.

Aspen Aerogels Trading Down 1.8%

NYSE ASPN opened at $4.97 on Thursday. The firm has a market capitalization of $411.91 million, a PE ratio of -3.65 and a beta of 2.99. The business’s 50-day moving average price is $5.50 and its two-hundred day moving average price is $4.39. The company has a current ratio of 2.89, a quick ratio of 2.54 and a debt-to-equity ratio of 0.32. Aspen Aerogels has a 12 month low of $2.30 and a 12 month high of $9.78.

Aspen Aerogels (NYSE:ASPN) last issued its quarterly earnings data on Thursday, August 6th. The construction company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Aspen Aerogels had a negative return on equity of 22.16% and a negative net margin of 48.64%.Aspen Aerogels has set its Q3 2026 guidance at -0.110–0.070 EPS. On average, analysts expect that Aspen Aerogels will post -0.8 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ASPN. Royal Bank of Canada boosted its stake in shares of Aspen Aerogels by 84.7% in the 1st quarter. Royal Bank of Canada now owns 56,419 shares of the construction company’s stock valued at $360,000 after purchasing an additional 25,880 shares during the last quarter. AQR Capital Management LLC bought a new position in Aspen Aerogels during the first quarter worth $960,000. Integrated Wealth Concepts LLC bought a new position in Aspen Aerogels during the first quarter worth $84,000. Goldman Sachs Group Inc. lifted its holdings in Aspen Aerogels by 89.7% in the first quarter. Goldman Sachs Group Inc. now owns 1,274,356 shares of the construction company’s stock valued at $8,143,000 after buying an additional 602,586 shares during the period. Finally, Caxton Associates LLP acquired a new position in Aspen Aerogels in the first quarter valued at $307,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Aspen Aerogels Company Profile

Aspen Aerogels, Inc, headquartered in Northborough, Massachusetts, develops and manufactures high-performance aerogel insulation materials and custom engineered solutions. Founded in 2001 as a spin-out from Department of Energy research, the company pursued an initial public offering on the NYSE in 2014 under the ticker ASPN. Aspen Aerogels combines proprietary aerogel formulations with advanced manufacturing processes to deliver products known for their low thermal conductivity, lightweight construction and robust mechanical properties.

The company’s product portfolio spans blanket insulation, boards, and custom shapes built around several proprietary brands, including Pyrogel, Cryogel and Spaceloft.